'It's the right call': GSK expresses no regrets on abandoning cell therapy as oligo strategy heats up

Summarizing GSK’s vision to investors last month, CEO Emma Walmsley reaffirmed that the British Big Pharma had decided to “end our investment in cell and gene therapy.” While this was hardly news to the audience—especially coming months after GSK axed cell therapy deals with Lycell and Immatics—it still served as a stark reminder that the company's development portfolio is swimming against the industry tide.